Literature DB >> 7240667

The effect of 131I for diagnostic purposes on serum thyroglobulin (hTg) levels in subjects with thyroidal disorders.

A J Van Herle, N Demeester-Mirkine, B Van Heuverswyn, J Dumont.   

Abstract

The concentration of serum thyroglobulin was measured in sera of subjects with various thyroid disorders, before and after the administration of tracer doses of 131I. The mean serum human thyroglobulin (hTg) concentration before administration of the isotope was 35.2 ng/ml +/- 7.8 (SE) in 13 subjects and 36.3 ng/ml +/- 7.9 (SE) 24 h after the administration of 131I. The data indicate that no significant release of thyroglobulin occurs 24 h after the administration of tracer doses of 131I. In 2 of the 3 subjects, however, in whom samples were obtained at 4 and 8 h after diagnostic administration of 131I, a modest rise in serum Tg levels was observed. Determinations of serum thyroglobulin levels within 24 h after the administration of a tracer dose of 131I are nevertheless valid providing one allows sufficient time to elapse for tracer decay.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240667     DOI: 10.1007/bf03349426

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

1.  Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs.

Authors:  D F Gardner; J Rothman; R D Utiger
Journal:  Clin Endocrinol (Oxf)       Date:  1979-12       Impact factor: 3.478

2.  Effect of therapy on serum thyroglobulin levels in patients with Graves' disease.

Authors:  R P Uller; A J Van Herle
Journal:  J Clin Endocrinol Metab       Date:  1978-05       Impact factor: 5.958

3.  Sequential study of the impairment of thyroid function in the early stage of subacute thyroiditis.

Authors:  D Glinoer; N Puttemans; A J Van Herle; M Camus; A M Ermans
Journal:  Acta Endocrinol (Copenh)       Date:  1974-09

4.  Serum thyroglobulin levels in healthy subjects and in patients with thyroid disease.

Authors:  G Torrigiani; D Doniach; I M Roitt
Journal:  J Clin Endocrinol Metab       Date:  1969-03       Impact factor: 5.958

5.  Serum albumin and antibodies in the diagnosis of thyroid cancer.

Authors:  L J DeGroot; K Hoye; S Refetoff; A J Van Herle; G T Asteris; H Rochman
Journal:  J Clin Endocrinol Metab       Date:  1977-12       Impact factor: 5.958

6.  Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.

Authors:  A J Herle; R P Uller
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

7.  Serum thyroglobulin in inhabitants of an endemic goiter region of New Guinea.

Authors:  A J Van Herle; J M Hershman; R W Hornabrook; I J Chopra
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

8.  Radioimmunoassay for measurement of thyroglobulin in human serum.

Authors:  A J Van Herle; R P Uller; N I Matthews; J Brown
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

9.  Correlation of sequential changes in serum thyroglobulin, triiodothyronine, and thyroxine in patients with Graves' disease and subacute thyroiditis.

Authors:  M Izumi; P R Larsen
Journal:  Metabolism       Date:  1978-04       Impact factor: 8.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.